Inhibrx, Inc. (INBX)

NASDAQ: INBX · IEX Real-Time Price · USD
34.98
-0.04 (-0.11%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-0.11%
Market Cap 1.66B
Revenue (ttm) 1.80M
Net Income (ttm) -241.36M
Shares Out 47.39M
EPS (ttm) -5.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 315,931
Open 34.81
Previous Close 35.02
Day's Range 34.77 - 35.08
52-Week Range 14.31 - 39.79
Beta 2.92
Analysts Buy
Price Target 35.00 (+0.06%)
Earnings Date May 6, 2024

About INBX

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of pat... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 19, 2020
Employees 172
Stock Exchange NASDAQ
Ticker Symbol INBX
Full Company Profile

Financial Performance

In 2023, Inhibrx's revenue was $1.80 million, a decrease of -17.88% compared to the previous year's $2.19 million. Losses were -$241.36 million, 66.2% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for INBX stock is "Buy." The 12-month stock price forecast is $35.0, which is an increase of 0.06% from the latest price.

Price Target
$35.0
(0.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeli...

6 weeks ago - PRNewsWire

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (N...

Other symbols: SNY
2 months ago - Business Wire

Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi

MILWAUKEE , Jan. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join https://www.ademilaw.com/cas...

2 months ago - PRNewsWire

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to tr...

Other symbols: SNY
2 months ago - Investopedia

INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms o...

2 months ago - Business Wire

Sanofi to Buy Rare-Disease Assets From Inhibrx

Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion.

Other symbols: SNY
2 months ago - WSJ

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday.

Other symbols: SNY
2 months ago - Reuters

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi's portfolio growth strategy and complement...

Other symbols: SNY
2 months ago - GlobeNewsWire

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 ass...

Other symbols: SNY
2 months ago - PRNewsWire

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

SAN DIEGO , Nov. 9, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipel...

5 months ago - PRNewsWire

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today ann...

5 months ago - PRNewsWire

Inhibrx Announces Participation in Upcoming Scientific Conferences

SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today an...

6 months ago - PRNewsWire

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announc...

7 months ago - PRNewsWire

Andreas Halvorsen's Firm Ups Inhibrx Stake

Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% fol...

8 months ago - GuruFocus

Inhibrx Announces $200 Million Private Placement Financing

SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncolog...

8 months ago - PRNewsWire

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipel...

8 months ago - PRNewsWire

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

SAN DIEGO , May 30, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced...

11 months ago - PRNewsWire

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

SAN DIEGO , May 8, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline,...

1 year ago - PRNewsWire

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

SAN DIEGO , April 26, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announc...

1 year ago - PRNewsWire

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

SAN DIEGO , March 6, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeli...

1 year ago - PRNewsWire

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

BELOIT, Wis. & SAN DIEGO--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic ...

1 year ago - Business Wire

Inhibrx Announces Participation in Upcoming Investor Conference

SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today an...

1 year ago - PRNewsWire

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

SAN DIEGO , Nov. 16, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today an...

1 year ago - PRNewsWire

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

SAN DIEGO , Nov. 7, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial r...

1 year ago - PRNewsWire

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

SAN DIEGO , Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced...

1 year ago - PRNewsWire